- Home
- GNSS vs MIST Comparison
GNSS vs MIST Comparison
Compare GNSS & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNSS
- MIST
- Stock Information
- Founded
- GNSS 1992
- MIST 2003
- Country
- GNSS United States
- MIST Canada
- Employees
- GNSS N/A
- MIST N/A
- Industry
- GNSS Consumer Electronics/Appliances
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- GNSS Consumer Staples
- MIST Health Care
- Exchange
- GNSS Nasdaq
- MIST Nasdaq
- Market Cap
- GNSS 169.5M
- MIST 81.5M
- IPO Year
- GNSS N/A
- MIST N/A
- Fundamental
- Price
- GNSS $3.75
- MIST $1.44
- Analyst Decision
- GNSS Strong Buy
- MIST Strong Buy
- Analyst Count
- GNSS 3
- MIST 3
- Target Price
- GNSS $5.08
- MIST $13.00
- AVG Volume (30 Days)
- GNSS 106.7K
- MIST 177.8K
- Earning Date
- GNSS 12-05-2024
- MIST 11-11-2024
- Dividend Yield
- GNSS N/A
- MIST N/A
- EPS Growth
- GNSS N/A
- MIST N/A
- EPS
- GNSS N/A
- MIST N/A
- Revenue
- GNSS $27,968,000.00
- MIST N/A
- Revenue This Year
- GNSS N/A
- MIST N/A
- Revenue Next Year
- GNSS $138.10
- MIST N/A
- P/E Ratio
- GNSS N/A
- MIST N/A
- Revenue Growth
- GNSS N/A
- MIST N/A
- 52 Week Low
- GNSS $1.51
- MIST $1.12
- 52 Week High
- GNSS $4.04
- MIST $3.52
- Technical
- Relative Strength Index (RSI)
- GNSS 60.29
- MIST 42.50
- Support Level
- GNSS $3.67
- MIST $1.41
- Resistance Level
- GNSS $3.94
- MIST $1.53
- Average True Range (ATR)
- GNSS 0.14
- MIST 0.07
- MACD
- GNSS -0.02
- MIST -0.01
- Stochastic Oscillator
- GNSS 77.78
- MIST 26.96
About GNSS Genasys Inc.
Genasys Inc is a provider of critical communications solutions designed to help keep people safe. The company is engaged in the design, development, and commercialization of directed and multidirectional sound technologies, voice broadcast products and location-based mass messaging solutions for emergency warning and workforce management. Its operating segment includes Hardware and Software. The company generates maximum revenue from the Hardware segment. Geographically, it derives a majority of revenue from the Americas region and also has its presence in the Asia Pacific and Europe, Middle East and Africa.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).